{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:45:05Z","timestamp":1780397105771,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Beijing Natural Science Foundation of China","award":["7162035"],"award-info":[{"award-number":["7162035"]}]},{"name":"Beijing high-level talent plan","award":["2015-3-040"],"award-info":[{"award-number":["2015-3-040"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81271522"],"award-info":[{"award-number":["81271522"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National High Technology Research and Development Program of China","award":["2014AA020610"],"award-info":[{"award-number":["2014AA020610"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Endocrinology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.mce.2016.12.029","type":"journal-article","created":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T02:32:51Z","timestamp":1483237971000},"page":"32-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["ESR1 and its antagonist fulvestrant in pituitary adenomas"],"prefix":"10.1016","volume":"443","author":[{"given":"Hua","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yake","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazhuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mce.2016.12.029_bib1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ecl.2014.10.007","article-title":"Cabergoline use for pituitary tumors and valvular disorders","volume":"44","author":"Auriemma","year":"2015","journal-title":"Endocrinol. Metab. Clin. North Am."},{"issue":"2","key":"10.1016\/j.mce.2016.12.029_bib2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ygyno.2016.03.006","article-title":"Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer","volume":"141","author":"Backes","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.mce.2016.12.029_bib3","first-page":"496e503","article-title":"Effects of short-term estradiol and norethindrone acetate treatment on the breasts of normal postmenopausal women","volume":"20","author":"Cheng","year":"2013","journal-title":"Menopause"},{"issue":"4","key":"10.1016\/j.mce.2016.12.029_bib4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1677\/ERC-08-0181","article-title":"Medical therapy for clinically non-functioning pituitary adenomas","volume":"15","author":"Colao","year":"2008","journal-title":"Endocr. Rel Cancer"},{"issue":"3","key":"10.1016\/j.mce.2016.12.029_bib5","doi-asserted-by":"crossref","first-page":"R223","DOI":"10.1530\/JME-14-0011","article-title":"Somatostatin receptor ligands and resistance to treatment in pituitary adenomas","volume":"52","author":"Cuevas-Ramos","year":"2014","journal-title":"J.\u00a0Mol. Endocrinol."},{"issue":"2","key":"10.1016\/j.mce.2016.12.029_bib7","doi-asserted-by":"crossref","first-page":"e9011","DOI":"10.1371\/journal.pone.0009011","article-title":"Timing-dependent actions of NGF required for cell differentiation","volume":"5","author":"Chung","year":"2010","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.mce.2016.12.029_bib8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1530\/eje.0.1350548","article-title":"Chronic treatment with CV 205\u2013502 restores the gonadal function in hyperprolactinemic males","volume":"135","author":"Colao","year":"1996","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"10.1016\/j.mce.2016.12.029_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ando.2014.10.002","article-title":"Medical therapies in pituitary adenomas: current rationale for the use and future perspectives","volume":"76","author":"Cuny","year":"2015","journal-title":"Ann. Endocrinol. Paris."},{"issue":"24","key":"10.1016\/j.mce.2016.12.029_bib10","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1158\/1078-0432.CCR-07-1598","article-title":"BCL-2 family proteins: critical checkpoints of apoptotic cell death","volume":"13","author":"Danial","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.mce.2016.12.029_bib11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1530\/EJE-14-0990","article-title":"Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth","volume":"172","author":"Delgrange","year":"2015","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"10.1016\/j.mce.2016.12.029_bib12","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1677\/ERC-09-0101","article-title":"Activation of RAF\/MEK\/ERK and PI3K\/AKT\/mTOR pathways in pituitary adenomas and their effects on downstream effectors","volume":"16","author":"Dworakowska","year":"2009","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.mce.2016.12.029_bib13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/cncr.20412","article-title":"The prevalence of pituitary adenomas","volume":"101","author":"Ezzat","year":"2004","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.mce.2016.12.029_bib14","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1172\/JCI60417","article-title":"EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas","volume":"121","author":"Fukuoka","year":"2011","journal-title":"J.\u00a0Clin. Invest"},{"key":"10.1016\/j.mce.2016.12.029_bib15","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12885-015-1267-0","article-title":"Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas","volume":"15","author":"Gao","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.mce.2016.12.029_bib16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2741\/e390","article-title":"Targeting rapid action of sex-steroid receptors in breast and prostate cancers","volume":"4","author":"Giovannelli","year":"2012","journal-title":"Front. Biosci. (Elite Ed."},{"key":"10.1016\/j.mce.2016.12.029_bib17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.mce.2014.11.015","article-title":"Estrogen receptors in breast carcinogenesis and endocrine therapy","volume":"418","author":"Huang","year":"2015","journal-title":"Mol. Cell Endocrinol."},{"issue":"6","key":"10.1016\/j.mce.2016.12.029_bib18","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1507\/endocrj.K08E-131","article-title":"Gonadotropin releasing hormone (GnRH) enhances annexin A5 mRNA expression through mitogen activated protein kinase (MAPK) in LbetaT2 pituitary gonadotrope cells","volume":"55","author":"Kawaminami","year":"2008","journal-title":"Endocr. J."},{"issue":"12","key":"10.1016\/j.mce.2016.12.029_bib19","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.jocn.2011.06.013","article-title":"Effects of an estrogen receptor antagonist on proliferation, prolactin secretion and growth factor expression in the MMQ pituitary prolactinoma cell line","volume":"18","author":"Leng","year":"2011","journal-title":"J.\u00a0Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.mce.2016.12.029_bib20","first-page":"268","article-title":"Effects of fulvestrant, an estrogen receptor antagonist, on MMQ cells and its mechanism","volume":"30","author":"Li","year":"2009","journal-title":"Neuro Endocrinol. Lett."},{"issue":"6","key":"10.1016\/j.mce.2016.12.029_bib21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1369\/jhc.2009.954644","article-title":"Immunocytochemical localization of sex steroid hormone receptors in normal human mammary gland","volume":"58","author":"Li","year":"2010","journal-title":"J.\u00a0Histochem Cytochem"},{"key":"10.1016\/j.mce.2016.12.029_bib22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.mce.2015.10.021","volume":"419","author":"Liu","year":"2016","journal-title":"role FSCN1 Migr. invasion Pituit. adenomas.Mol Cell Endocrinol"},{"issue":"2","key":"10.1016\/j.mce.2016.12.029_bib23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11060-010-0326-2","article-title":"Effects of estrogen receptor antagonist on biological behavior and expression of growth factors in the prolactinoma MMQ cell line","volume":"102","author":"Lv","year":"2011","journal-title":"J.\u00a0Neurooncol"},{"issue":"8","key":"10.1016\/j.mce.2016.12.029_bib24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2174\/138920206779315737","article-title":"Estrogen signaling multiple pathways to impact gene transcription","volume":"7","author":"Marino","year":"2006","journal-title":"Curr. genomics"},{"issue":"4","key":"10.1016\/j.mce.2016.12.029_bib25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3816\/CBC.2008.n.040","article-title":"Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer","volume":"8","author":"McCormack","year":"2008","journal-title":"Clin. Breast Cancer"},{"issue":"6","key":"10.1016\/j.mce.2016.12.029_bib26","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1210\/jc.2008-1826","article-title":"Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and soma-totropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly","volume":"94","author":"Neto","year":"2009","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2016.12.029_bib27","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/jnci\/87.10.746","article-title":"Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer","volume":"87","author":"Osborne","year":"1995","journal-title":"J.\u00a0Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.mce.2016.12.029_bib28","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1750-3639.2007.00081.x","article-title":"Papillary tumor of the pineal region and spindle cell oncocytoma of the pituitary: new tumor entities in the 2007 WHO Classification","volume":"17","author":"Roncaroli","year":"2007","journal-title":"Brain Pathol."},{"issue":"11","key":"10.1016\/j.mce.2016.12.029_bib29","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1073\/pnas.1523693113","article-title":"Pten loss promotes MAPK pathway dependency in HER2\/neu breast carcinomas","volume":"113","author":"Saya","year":"2016","journal-title":"PNAS"},{"key":"10.1016\/j.mce.2016.12.029_bib30","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3171\/jns.1986.65.6.0733","article-title":"Pathology of invasive pituitary tumors with special reference to functional classification","volume":"165","author":"Scheithauer","year":"1986","journal-title":"J.\u00a0Neurosurg."},{"issue":"1","key":"10.1016\/j.mce.2016.12.029_bib31","first-page":"296","article-title":"Association between estrogen receptor 1 (ESR1) genetic variations and cancer risk: a meta-analysis","volume":"20","author":"Sun","year":"2015","journal-title":"J.\u00a0BUON"},{"issue":"2","key":"10.1016\/j.mce.2016.12.029_bib32","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/annonc\/mdj047","article-title":"A\u00a0new treatment option for advanced breast cancer: tolerability versus existing agents","volume":"17","author":"Vergote","year":"2006","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.mce.2016.12.029_bib33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11060-013-1276-2","article-title":"Low levels of PRB3 mRNA are associated with dopamine-agonist resistance and tumor recurrence in prolactinomas","volume":"116","author":"Wang","year":"2014","journal-title":"J.\u00a0Neurooncol"},{"issue":"6","key":"10.1016\/j.mce.2016.12.029_bib34","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1158\/1078-0432.CCR-09-1692","article-title":"Death receptor agonists as a targeted therapy for cancer","volume":"16","author":"Wiezorek","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.mce.2016.12.029_bib35","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1158\/1078-0432.CCR-12-3039","article-title":"Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma","volume":"19","author":"Wik","year":"2013","journal-title":"Clin. Cancer Res."}],"container-title":["Molecular and Cellular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720716305524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720716305524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T10:11:32Z","timestamp":1573639892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303720716305524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":34,"alternative-id":["S0303720716305524"],"URL":"https:\/\/doi.org\/10.1016\/j.mce.2016.12.029","relation":{},"ISSN":["0303-7207"],"issn-type":[{"value":"0303-7207","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ESR1 and its antagonist fulvestrant in pituitary adenomas","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mce.2016.12.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}